Glenmede Trust CO Na Corcept Therapeutics Inc Transaction History

Glenmede Trust CO Na

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$16.78 - $27.3 $15,169 - $24,679	-904 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.46 - $19.98 $448 - $719	36 Added 4.15%	904 $15,000
Q2 2020 Aug 14, 2020	SELL	$11.0 - $18.26 $2,211 - $3,670	-201 Reduced 18.8%	868 $14,000
Q4 2019 Feb 12, 2020	BUY	$12.06 - $16.96 $4,221 - $5,936	350 Added 48.68%	1,069 $12,000
Q3 2019 Nov 14, 2019	BUY	$10.41 - $14.66 $1,582 - $2,228	152 Added 26.81%	719 $10,000
Q4 2018 Feb 14, 2019	BUY	$11.29 - $17.19 $474 - $721	42 Added 8.0%	567 $7,000
Q2 2018 Aug 15, 2018	BUY	$15.3 - $19.69 $8,032 - $10,337	525 New	525 $8,000
Q4 2017 Feb 15, 2018	SELL	$15.77 - $20.72 $338,455 - $444,692	-21,462 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $263,982 - $414,216	21,462	21,462 $0

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.3B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.